229 related articles for article (PubMed ID: 34253594)
21. Drug-regulated CD33-targeted CAR T cells control AML using clinically optimized rapamycin dosing.
Appelbaum J; Price AE; Oda K; Zhang J; Leung WH; Tampella G; Xia D; So PP; Hilton SK; Evandy C; Sarkar S; Martin U; Krostag AR; Leonardi M; Zak DE; Logan R; Lewis P; Franke-Welch S; Ngwenyama N; Fitzgerald M; Tulberg N; Rawlings-Rhea S; Gardner RA; Jones K; Sanabria A; Crago W; Timmer J; Hollands A; Eckelman B; Bilic S; Woodworth J; Lamble A; Gregory PD; Jarjour J; Pogson M; Gustafson JA; Astrakhan A; Jensen MC
J Clin Invest; 2024 Mar; 134(9):. PubMed ID: 38502193
[TBL] [Abstract][Full Text] [Related]
22. Targeting C-type lectin-like molecule-1 for antibody-mediated immunotherapy in acute myeloid leukemia.
Zhao X; Singh S; Pardoux C; Zhao J; Hsi ED; Abo A; Korver W
Haematologica; 2010 Jan; 95(1):71-8. PubMed ID: 19648166
[TBL] [Abstract][Full Text] [Related]
23. Cooperative CAR targeting to selectively eliminate AML and minimize escape.
Haubner S; Mansilla-Soto J; Nataraj S; Kogel F; Chang Q; de Stanchina E; Lopez M; Ng MR; Fraser K; Subklewe M; Park JH; Wang X; Rivière I; Sadelain M
Cancer Cell; 2023 Nov; 41(11):1871-1891.e6. PubMed ID: 37802054
[TBL] [Abstract][Full Text] [Related]
24. Effective Killing of Acute Myeloid Leukemia by TIM-3 Targeted Chimeric Antigen Receptor T Cells.
Lee WS; Ye Z; Cheung AMS; Goh YPS; Oh HLJ; Rajarethinam R; Yeo SP; Soh MK; Chan EHL; Tan LK; Tan SY; Chuah C; Chng WJ; Connolly JE; Wang CI
Mol Cancer Ther; 2021 Sep; 20(9):1702-1712. PubMed ID: 34158344
[TBL] [Abstract][Full Text] [Related]
25. Chimeric Antigen Receptors Incorporating D Domains Targeting CD123 Direct Potent Mono- and Bi-specific Antitumor Activity of T Cells.
Qin H; Edwards JP; Zaritskaya L; Gupta A; Mu CJ; Fry TJ; Hilbert DM; LaFleur DW
Mol Ther; 2019 Jul; 27(7):1262-1274. PubMed ID: 31043341
[TBL] [Abstract][Full Text] [Related]
26. Preclinical Assessment of Efficacy and Safety Analysis of CAR-T Cells (ISIKOK-19) Targeting CD19-Expressing B-Cells for the First Turkish Academic Clinical Trial with Relapsed/Refractory ALL and NHL Patients.
Taştan C; Kançağı DD; Turan RD; Yurtsever B; Çakırsoy D; Abanuz S; Yılancı M; Seyis U; Özer S; Mert S; Kayhan CK; Tokat F; Açıkel Elmas M; Birdoğan S; Arbak S; Yalçın K; Sezgin A; Kızılkılıç E; Hemşinlioğlu C; İnce Ü; Ratip S; Ovalı E
Turk J Haematol; 2020 Nov; 37(4):234-247. PubMed ID: 32755128
[TBL] [Abstract][Full Text] [Related]
27. CAR-T cells targeting CLL-1 as an approach to treat acute myeloid leukemia.
Wang J; Chen S; Xiao W; Li W; Wang L; Yang S; Wang W; Xu L; Liao S; Liu W; Wang Y; Liu N; Zhang J; Xia X; Kang T; Chen G; Cai X; Yang H; Zhang X; Lu Y; Zhou P
J Hematol Oncol; 2018 Jan; 11(1):7. PubMed ID: 29316944
[TBL] [Abstract][Full Text] [Related]
28. Treatment of advanced leukemia in mice with mRNA engineered T cells.
Barrett DM; Zhao Y; Liu X; Jiang S; Carpenito C; Kalos M; Carroll RG; June CH; Grupp SA
Hum Gene Ther; 2011 Dec; 22(12):1575-86. PubMed ID: 21838572
[TBL] [Abstract][Full Text] [Related]
29. T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells.
Zah E; Lin MY; Silva-Benedict A; Jensen MC; Chen YY
Cancer Immunol Res; 2016 Jun; 4(6):498-508. PubMed ID: 27059623
[TBL] [Abstract][Full Text] [Related]
30. Developing a membrane-proximal CD33-targeting CAR T cell.
Freeman R; Shahid S; Khan AG; Mathew SC; Souness S; Burns ER; Um JS; Tanaka K; Cai W; Yoo S; Dunbar A; Park Y; McAvoy D; Hosszu KK; Levine RL; Boelens JJ; Lorenz IC; Brentjens RJ; Daniyan AF
J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38772686
[TBL] [Abstract][Full Text] [Related]
31. Targeting CD33 in Chemoresistant AML Patient-Derived Xenografts by CAR-CIK Cells Modified with an Improved SB Transposon System.
Rotiroti MC; Buracchi C; Arcangeli S; Galimberti S; Valsecchi MG; Perriello VM; Rasko T; Alberti G; Magnani CF; Cappuzzello C; Lundberg F; Pande A; Dastoli G; Introna M; Serafini M; Biagi E; Izsvák Z; Biondi A; Tettamanti S
Mol Ther; 2020 Sep; 28(9):1974-1986. PubMed ID: 32526203
[TBL] [Abstract][Full Text] [Related]
32. Siglec-6 is a novel target for CAR T-cell therapy in acute myeloid leukemia.
Jetani H; Navarro-Bailón A; Maucher M; Frenz S; Verbruggen C; Yeguas A; Vidriales MB; González M; Rial Saborido J; Kraus S; Mestermann K; Thomas S; Bonig H; Luu M; Monjezi R; Mougiakakos D; Sauer M; Einsele H; Hudecek M
Blood; 2021 Nov; 138(19):1830-1842. PubMed ID: 34289026
[TBL] [Abstract][Full Text] [Related]
33. A novel IgG-based FLT3xCD3 bispecific antibody for the treatment of AML and B-ALL.
Mehta NK; Pfluegler M; Meetze K; Li B; Sindel I; Vogt F; Marklin M; Heitmann JS; Kauer J; Osburg L; Zekri L; Bühring HJ; Mueller S; Hörner S; Baeuerle PA; Michaelson JS; Jung G; Salih HR
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35288466
[TBL] [Abstract][Full Text] [Related]
34. Synergistic and persistent effect of T-cell immunotherapy with anti-CD19 or anti-CD38 chimeric receptor in conjunction with rituximab on B-cell non-Hodgkin lymphoma.
Mihara K; Yanagihara K; Takigahira M; Kitanaka A; Imai C; Bhattacharyya J; Kubo T; Takei Y; Yasunaga S; Takihara Y; Kimura A
Br J Haematol; 2010 Oct; 151(1):37-46. PubMed ID: 20678160
[TBL] [Abstract][Full Text] [Related]
35. CD19/CD22 Dual-Targeted CAR T-cell Therapy for Relapsed/Refractory Aggressive B-cell Lymphoma: A Safety and Efficacy Study.
Wei G; Zhang Y; Zhao H; Wang Y; Liu Y; Liang B; Wang X; Xu H; Cui J; Wu W; Zhao K; Nagler A; Chang AH; Hu Y; Huang H
Cancer Immunol Res; 2021 Sep; 9(9):1061-1070. PubMed ID: 34290048
[TBL] [Abstract][Full Text] [Related]
36. Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies.
Rodgers DT; Mazagova M; Hampton EN; Cao Y; Ramadoss NS; Hardy IR; Schulman A; Du J; Wang F; Singer O; Ma J; Nunez V; Shen J; Woods AK; Wright TM; Schultz PG; Kim CH; Young TS
Proc Natl Acad Sci U S A; 2016 Jan; 113(4):E459-68. PubMed ID: 26759369
[TBL] [Abstract][Full Text] [Related]
37. Construction of a new anti-CD19 chimeric antigen receptor and the anti-leukemia function study of the transduced T cells.
An N; Tao Z; Li S; Xing H; Tang K; Tian Z; Rao Q; Wang M; Wang J
Oncotarget; 2016 Mar; 7(9):10638-49. PubMed ID: 26840021
[TBL] [Abstract][Full Text] [Related]
38. CLT030, a leukemic stem cell-targeting CLL1 antibody-drug conjugate for treatment of acute myeloid leukemia.
Jiang YP; Liu BY; Zheng Q; Panuganti S; Chen R; Zhu J; Mishra M; Huang J; Dao-Pick T; Roy S; Zhao X; Lin J; Banik G; Hsi ED; Mandalam R; Junutula JR
Blood Adv; 2018 Jul; 2(14):1738-1749. PubMed ID: 30037800
[TBL] [Abstract][Full Text] [Related]
39. A modular and controllable T cell therapy platform for acute myeloid leukemia.
Benmebarek MR; Cadilha BL; Herrmann M; Lesch S; Schmitt S; Stoiber S; Darwich A; Augsberger C; Brauchle B; Rohrbacher L; Oner A; Seifert M; Schwerdtfeger M; Gottschlich A; Rataj F; Fenn NC; Klein C; Subklewe M; Endres S; Hopfner KP; Kobold S
Leukemia; 2021 Aug; 35(8):2243-2257. PubMed ID: 33414484
[TBL] [Abstract][Full Text] [Related]
40. Redirecting Specificity of T cells Using the Sleeping Beauty System to Express Chimeric Antigen Receptors by Mix-and-Matching of VL and VH Domains Targeting CD123+ Tumors.
Thokala R; Olivares S; Mi T; Maiti S; Deniger D; Huls H; Torikai H; Singh H; Champlin RE; Laskowski T; McNamara G; Cooper LJ
PLoS One; 2016; 11(8):e0159477. PubMed ID: 27548616
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
